Screener / SEC EDGAR /CIK 0001061983 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Cytokinetics Inc CYTK

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of CYTK's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Jul 29, 2025
Questions asked 3 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 3 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 2 of 2 closing letter

Half the closed reviews took 34 days or less from the first letter to the closing letter.

Form 10-K for the fiscal year ended December 31, 2024

2025-07-29 to 2025-08-13 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-08-13
Results discussion (MD&A)
Results of Operations · Research and Development Expenses, page 46
SEC asked
Please provide revised disclosure to be included in future filings to break out research and development expenses by clinical program or trial. For amounts that are not tracked by program, provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e.
Rest of the question

by nature or type of expense) for each period presented which should reconcile to total research and development expense on the Statements of Operations. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

CYTK answered
The Company respectfully acknowledges the Staff’s comment and will revise its future filings to include the following disclosure to explain research and development expenses, starting with the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025. The following disclosure is based on the Company’s second quarter research and development expenses and therefore addresses research and development expenses for the three and six months ended June 30, 2025 and 2024.

Research and Development Expenses

We incur research and development expenses associated with both
Rest of the answer

partnered and our own research activities, which we finance from our own cash-on-hand, financing arrangements with third parties, and reimbursement from our collaboration partners.

Research and development expenses for the three and six months ended

June 30, 2025 and 2024, were as follows (in thousands):

Three Months Ended

Six Months Ended

June 30,

2025

2024

Increase

External Costs:

Aficamten

$

29,390

20,958

8,432

58,938

44,155

14,783

Omecamtiv Mecarbil

3,967

954

3,013

7,564

6,680

884

Other programs

3,025

2,887

138

6,398

5,889

509

Unallocated

21,213

9,314

11,899

29,553

17,068

12,485

Total external costs

57,595

34,113

23,482

102,453

73,792

28,661

Internal Costs:

Employee related

41,109

32,634

8,475

81,136

63,934

17,202

Facilities, lab supplies and other

13,850

12,850

1,000

28,806

23,441

5,365

Total internal costs

54,959

45,484

9,475

109,942

87,375

22,567

Total research and development expense

112,554

79,597

32,957

212,395

161,167

51,228

Research and development expenses consist of external costs including contract research and manufacturing and consulting expenses. Aficamten external costs increased for the three and six months ended June 30, 2025, compared to the three and six months ended June 30, 2024, due primarily to the advancement of the ACACIA-HCM trial. Omecamtiv Mecarbil expenses increased in 2025 due to the COMET trial commencing in the fourth quarter of 2024. Unallocated external costs consist primarily of medical affairs, regulatory, quality and biostatistics.

We continue to develop aficamten to treat both oHCM and nHCM in three additional clinical trials, as follows: (i) MAPLE-HCM is our Phase 3 clinical trial of aficamten as a monotherapy for patients with oHCM, (ii) ACACIA-HCM is a Phase 3 clinical trial for patients with symptomatic nHCM, and (iii) CEDAR-HCM, our placebo-controlled and open-label extension clinical trial to evaluate the efficacy, pharmacokinetics (PK) and safety of aficamten in a pediatric population with symptomatic oHCM. Additionally, we have FOREST-HCM which is an open label extension study designed to assess the long term safety and tolerability of aficamten in patients with HCM.

We continue to develop omecamtiv mecarbil in COMET-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic HFrEF with severely reduced ejection fraction.

* * * * *

Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding this response letter to me at (949) 929-5744.

Read in the reply
In its next report

First report after the company's reply of Aug 8, 2025: 10-Q filed Nov 5, 2025 ↗, against the 10-Q filed May 6, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2025-08-13

Form 10-K for the Fiscal Year Ended December 31, 2020

2021-09-22 to 2021-10-26 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2021-10-26
Revenue
Note 3. Research and Development Arrangements, page 92
SEC asked (1)
We note that you entered into a series of transactions with RTW Royalty Holdings Designated Activity Company and Ji Xing, which include a licensing and collaboration arrangement, the sale of your common stock, and your interest in future royalties on net sales of products containing the compound mavacamten.
Rest of the question

Please tell us and explain in more detail how you determined the total consideration to be $160 million related to these arrangements and how you allocated the consideration to each unit of accounting for these arrangements under ASC 820 and ASC 606.

CYTK answered
The Company acknowledges the Staff’s comment.

On July 14, 2020, the Company entered into a series of agreements (collectively, the “Agreements”) with each of RTW Royalty

Holdings Designated Activity Company (f/k/a Dolya Holdco 19 Designated Activity Company) (“RTW Royalty Holdings”), Ji Xing Pharmaceuticals Limited (“Ji Xing”), RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW

Venture Fund Limited, which included a License and Collaboration Agreement with Ji Xing (the “License and Collaboration Agreement”), a Funding Agreement with RTW Royalty Holdings (the “Funding
Rest of the answer

Agreement”), a Royalty Purchase

Agreement with RTW Royalty Holdings (the “Royalty Purchase Agreement”), and a series of Common Stock Purchase Agreements (the “Common Stock Purchase Agreements”) with each of RTW Master Fund, Ltd., RTW Innovation Master Fund,

Ltd., and RTW Venture Fund Limited (the contract counterparties to the Common Stock Purchase Agreements, collectively, the “RTW Common Stock Investors”).

In assessing the accounting for the Agreements, the Company first determined that the License and Collaboration Agreement falls under the scope of ASC 808 as a collaboration agreement. However, the Company also determined that certain provisions within the License and Collaboration Agreement, including the transfer of the license and the provision of pharmaceutical product supply services in the future that are further discussed below, constitute transactions with a customer and therefore fall under the scope of ASC 606.

Next, the Company considered the guidance in ASC 606-10-25-9, which states the following:

An entity shall combine two or more contracts entered into at or near the same time with the same customer (or related parties of the customer) and account for the contracts as a single contract if one or more of the following criteria are met:

a. The contracts are negotiated as a package with a single commercial objective.

b. The amount of consideration to be paid in one contract depends on the price or performance of the other contract.

c. The goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation in accordance with paragraphs 606-10-25-14 through 25-22.

280 East Grand Avenue

· South San Francisco · CA ·94080

Each of the Agreements were entered into with parties that are affiliated and in contemplation of one another and, accordingly, based on the above guidance, we have assessed the accounting for these transactions in the aggregate.

Upon entering into the Agreements, the Company was entitled to the following payments from RTW Royalty Holdings, Ji Xing and the RTW Common

Stock Investors as outlined in the Agreements:

License and Collaboration Agreement

$

25,000,000

Royalty Purchase Agreement

85,000,000

Common Stock Purchase Agreement

50,000,000

Total Arrangement Consideration

160,000,000

We also considered whether the development milestones contained in the License and Collaboration Agreement should be included in unconstrained arrangement consideration. Due to the uncertain nature of developing pharmaceutical products, including the inherent risk of development and approval by regulatory authorities, we are unable to estimate if and when the development milestone payments could be achieved or become due and, accordingly, we consider the milestone payments to be fully constrained and have excluded the milestone payments from the arrangement consideration to be allocated to the transaction price at inception.

The License and Collaboration Agreement also contains provisions for milestone payments and royalties to be paid upon commercialization. Any consideration related to sales-based milestone payments and royalties will be recognized when the related sales occur under the salesand usage-based royalty exception as these amounts have been determined to relate predominantly to the license and, accordingly, have been excluded from the arrangement consideration to be allocated to the transaction price.

To determine the allocation of arrangement consideration to the various units of accounting the Company considered the guidance in ASC 606-10-15-4, which states the following:

A contract with a customer may be partially within the scope of this Topic and partially within the scope of other Topics listed in paragraph 606-10-15-2.

a. If the other Topics specify how to separate and/or initially measure one or more parts of the contract, then an entity shall first apply the separation and/or measurement guidance in those Topics. An entity shall exclude from the transaction price the amount of the part (or parts) of the contract that are initially measured in accordance with other Topics and shall b. apply paragraphs 606-10-32-28 through 32-41 to allocate the amount of the transaction price that remains (if any) to each performance obligation within the scope of this Topic and to any other parts of the contract identified by paragraph 606-10-15-4(b).

c. If the other Topics do not specify how to separate and/or initially measure one or more parts of the contract, then the entity shall apply the guidance in this Topic to separate and/or initially measure the part (or parts) of the contract.

In accordance with ASC

820, Fair Value Measurement, and ASC 606, Revenue from Contracts with Customers, the Company determined that the $160 million of arrangement consideration should first be allocated to the Royalty Purchase Agreement and the Common

Stock Purchase Agreements based on their respective fair values, with the residual allocated to the License and Collaboration Agreement units of accounting as follows (in thousands):

Sale of mavacamten royalty rights (fair value)

87,000

Sale of common stock (fair value)

36,499

License & collaboration agreement (residual)

36,501

Total arrangement consideration

160,000

The above amounts were determined as follows:

•

The fair value of the Royalty Purchase Agreement was estimated to be $87 million and was determined using an income approach method based on management’s estimates of the discounted cash flows to be received over the term of the related royalty agreement.

The fair value of the stock sold under the Common Stock Purchase Agreements was estimated to be

$36.5 million. The Common Stock Purchase Agreements provided for the sale and issuance of an aggregate of 2.0 million shares of common stock (the “Shares”) to RTW for $50 million. Under the terms of the Common Stock Purchase

Agreement, RTW agreed to certain trading and other restrictions with respect to the Shares for a period of two years from the closing date. The restrictions resulted in a $13.5 million premium being paid by RTW that was determined by analyzing the holding period discount applied to the 30-day average stock price as of July 14, 2020. The fair value of the common stock was estimated to equal the $50 million of cash received less the premium paid by the RTW Common Stock Investors.

As noted above, $36.5 million was allocated to the License and Collaboration Agreement. While this was the residual after first allocating the arrangement consideration to the sales of the mavacamten royalty rights pursuant to the Royalty Purchase Agreement and common stock pursuant to the Common Stock Purchase Agreements, we assessed the reasonableness of this amount by using an income approach method based on management’s estimates of the discounted cash flows to be received over the term of the license granted under the License and Collaboration Agreement and concluded the

$36.5 million was reasonable.

We did not allocate any of the consideration to the Funding Agreement. Obtaining funds under this agreement is at the discretion of the Company and contingent upon certain development milestones that were not probable of achievement when the Funding Agreement was entered into. The continued development of the product, which is a condition to the disbursement of funding under the Funding Agreement, is at the discretion of the Company as is the decision of whether to borrow funds under the Funding Agreement.

Read in the reply
In its next report

First report after the company's reply of Oct 13, 2021: 10-Q filed Nov 5, 2021 ↗, against the 10-Q filed Aug 6, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 3. Research and Development Arrangements, page 92
SEC asked (2)
We further note that under the license and collaboration arrangement you concluded that there was one performance obligation relating to the license of functional intellectual property, you satisfied this obligation, and recognized $36.5 million in revenue during fiscal 2020.
Rest of the question

Please explain to us in more detail how you determined that there was one performance obligation under this arrangement under ASC 606 and that you satisfied the obligation to recognize this revenue up-front.

CYTK answered
The Company acknowledges the Staff’s comments.

Under the terms of the License and Collaboration Agreement the Company granted an exclusive license to develop and commercialize Cytokinetics’ proprietary small molecule cardiac myosin inhibitor product referred to as aficamten (a/k/a CK-274) (the “Product”) in the greater China region, including mainland China, Hong Kong, Macau, and Taiwan (collectively, the “Territory”) to Ji Xing.

In determining whether the license represents a distinct performance obligation the Company considered that under the License and Collaboration Agreement Ji Xing
Rest of the answer

is responsible for the development and commercialization of the Product at its own cost and

Cytokinetics is not required to provide any research or related services to further develop the licensed product in the Territory. Ji Xing can develop the Product for sale in China on its own and has the capability and resources to do so. Thus, the

Company concluded that Ji Xing can benefit from the license independent of any services or assistance from Cytokinetics and that the license is separately identifiable from other provisions in the License and Collaboration Agreement.

The License and Collaboration Agreement also contains the following provisions that were evaluated to determine whether they were performance obligations to which arrangement consideration should be allocated.

Assistance with transferring the license technology to Ji Xing

Under the terms of the License and Collaboration Agreement Cytokinetics performed an initial technology transfer, [***]. The Company also agreed to make its personnel available after the technology transfer period [***]. While Cytokinetics has agreed to provide such assistance if requested by Ji Xing, the provisioning of such assistance is a matter of convenience and is considered distinct from the license as such assistance is not necessary for Ji Xing to benefit from the license.

Participation on Joint Steering, Development, and Commercialization Committees

Under the terms of the License and Collaboration Agreement, Cytokinetics agreed to participate on the joint steering, development and commercialization committees that are or will be set up under the License and Collaboration Agreement to develop and commercialize the Product in the Territory. The Company expects that no more than 7 of its employees will provide services on these committees and such services are not expected to result in a significant level of effort or costs. The Company also considered participation on the committees from a qualitative perspective. The committees will include an equal number of representatives from Cytokinetics and Ji Xing and decisions will be made based on unanimous vote with each representative having one vote. [***]. Subject to the License and Collaboration Agreement, Ji Xing [***]. The primary functions of these committees are to facilitate governance under the terms of the License and Collaboration Agreement and to keep Cytokinetics informed of Ji Xing’s plans for the development and commercialization of the Product in the Territory [***]. The Company does not believe that participation on the committees is substantive to the continued development of the Product. Further, Ji Xing can develop the product for sale in China on its own, has the capability and/or resources to do so, and participation on the committees is not substantive to the continued development of the Product. Based on these qualitative and quantitative factors, performance on the committees was concluded to be immaterial within the context of the contract. The Company also expects that any costs or reimbursement for participating on these committees will be insignificant. Thus, the Company concluded that committee participation is immaterial in the context of the License and Collaboration Agreement and no arrangement consideration was allocated thereto.

Product supply

In accordance with the License and Collaboration Agreement, the parties have entered into a development supply agreement for clinical supply by or on behalf of Cytokinetics to Ji Xing for its development in the Territory. Under the terms of the License and Collaboration Agreement the parties will [***] to manufacture the Product using active pharmaceutical ingredients (“API”) supplied by or on behalf of Cytokinetics. Upon [***] for the manufacture and supply of the Product (using API supplied by Cytokinetics). [***]. [***]. [***]. [***].

The License and Collaboration Agreement also contains various other provisions [***]. We assessed each of these provisions and concluded they did not represent material rights or performance obligations.

We assessed the

License and Collaboration Agreement in accordance with ASC 606 and concluded there is one performance obligation, which is for the delivery of the license of functional intellectual property. This performance obligation was satisfied, and we recognized the residual allocation of arrangement consideration as revenue of $36.5 million in 2020.

The Company acknowledges that the adequacy and accuracy of the disclosures in its filing with the Commission are the responsibility of the Company. The Company acknowledges that Staff comments or changes to disclosures in response to Staff comments do not foreclose the

Commission from taking any action with respect to the filing. We appreciate the Staff’s assistance in this process and would be pleased to discuss with you at your earliest convenience any additional comments the Staff may have.

Read in the reply
In its next report

First report after the company's reply of Oct 13, 2021: 10-Q filed Nov 5, 2021 ↗, against the 10-Q filed Aug 6, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2021-10-26

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 6 letters filed since 2021-09-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CYTK/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.